Usual Care Intervention Research Evaluating the Impact of a Personalized Pharmaceutical Plan on the Duration of Opioid Treatment in Non-cancerous Pain (PPP-Care)

June 4, 2026 updated by: University Hospital, Rouen

Many treatments with WHO grade III opioids are being introduced in the rheumatology department for non-cancerous pain. The duration of this treatment prescribed at discharge is often uncontrolled and sometimes leads to significant addiction.

The team at the local pain center recommends an average duration of 28 days for this type of pain. There is a full-time pharmacy intern in the rheumatology department.

The aim of this work is to evaluate the impact of a targeted pharmaceutical interview on the duration of the morphine treatment initiated during hospitalization.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

100

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Rouen, France
        • Rouen University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age ≥ 18 and < 75 years old when entering the rheumatology department
  • Hospitalization in the rheumatology department
  • Patient with acute non-traumatic musculoskeletal disease
  • Patient not taking grade III opioid treatment
  • Patient affiliated to a social security scheme
  • Patient having read and understood the information letter and signed the consent form
  • Patient present on a day which the pharmacy intern is present

Exclusion Criteria:

  • Presence of cancer, fibromyalgia, already diagnosed at inclusion
  • Patient does not understand French
  • Patient with Current or past opioid addiction
  • Person deprived of liberty by administrative or judicial decision

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Patient with targeted pharmaceutical interview
Specific information about treatment delivered by pharmacist
Behavioral: Admission conciliation interview
Previous treatment conciliation at hospital admission
Behavioral: Discharge conciliation interview
Allocated treatment during hospital stay
Behavioral: Targeted pharmaceutical interview
Specific information about treatment delivered by pharmacist
Other: Patient without targeted pharmaceutical interview
No Specific information about treatment delivered by pharmacist
Behavioral: Admission conciliation interview
Previous treatment conciliation at hospital admission
Behavioral: Discharge conciliation interview
Allocated treatment during hospital stay

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Total duration of opioid treatment
Time Frame: 6 months
6 months

Secondary Outcome Measures

Outcome Measure
Time Frame
Rate of patients exceeding 28 days of cumulative duration of treatment
Time Frame: 6 months
6 months
Rate of patients exceeding 90 days of cumulative duration of treatment
Time Frame: 6 months
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Rouen

Investigators

  • Principal Investigator: Olivier VITTECOQ, Pr, University Hospital, Rouen
  • Principal Investigator: Remi VARIN, Pr, University Hospital, Rouen
  • Principal Investigator: Catherine CHENAILLER, Dr, University Hospital, Rouen

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 6, 2020

Primary Completion (Actual)

August 28, 2023

Study Completion (Actual)

August 28, 2023

Study Registration Dates

First Submitted

February 4, 2020

First Submitted That Met QC Criteria

January 17, 2022

First Posted (Actual)

January 19, 2022

Study Record Updates

Last Update Posted (Actual)

June 5, 2026

Last Update Submitted That Met QC Criteria

June 4, 2026

Last Verified

September 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • 2019/0025/HP
  • 2019-A00515-52 (Other Identifier: ANSM)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Opioid Use

Clinical Trials on Admission conciliation interview

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe